Exploration of novel C-glucoside formation and application for SGLT2 inhibitors - Discovery of canagliflozin as a SGL T2 inhibitor

Shigeki Sakamaki, Eiji Kawanishi, Sumihiro Nomura

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Inhibition of sodium glucose co-transporter 2 (SGLT2) in vivo increases urinary glucose excretion (UGE) and controls blood glucose levels in hyperglycemic animals. T-1095 is the first orally active SGLT2 inhibitor, and it was discovered by optimizing the natural glucosyl product phlorizin. We focused on aryl-C-glucosides and optimized the analogs, resulting in the discovery of canagliflozin, which is metabolically more stable than T-1095. Canagliflozin markedly induced UGE compared with that of T-1095 because of its excellent pharmacokinetic properties in vivo and its high potency for inhibiting SGLT2. Canagliflozin was selected as a clinical candidate for treating type 2 diabetes mellitus and was approved in the USA and EU in 2013 and in Japan in 2014. In this study, we describe the synthesis of new C-glucoside analogs using a palladium-catalyzed crosscoupling reaction of glucal boronate and its application as an SGLT2 inhibitor.

Original languageEnglish
Pages (from-to)877-884
Number of pages8
JournalYuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry
Volume74
Issue number9
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Symporters
Glucosides
Sodium
Glucose
Phlorhizin
Calcium Gluconate
Pharmacokinetics
Palladium
Medical problems
Blood Glucose
Canagliflozin
Animals
T 1095

All Science Journal Classification (ASJC) codes

  • Organic Chemistry

Cite this

Exploration of novel C-glucoside formation and application for SGLT2 inhibitors - Discovery of canagliflozin as a SGL T2 inhibitor. / Sakamaki, Shigeki; Kawanishi, Eiji; Nomura, Sumihiro.

In: Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, Vol. 74, No. 9, 01.01.2016, p. 877-884.

Research output: Contribution to journalReview article

@article{e7cb54f3411a440c89d4a03308167afc,
title = "Exploration of novel C-glucoside formation and application for SGLT2 inhibitors - Discovery of canagliflozin as a SGL T2 inhibitor",
abstract = "Inhibition of sodium glucose co-transporter 2 (SGLT2) in vivo increases urinary glucose excretion (UGE) and controls blood glucose levels in hyperglycemic animals. T-1095 is the first orally active SGLT2 inhibitor, and it was discovered by optimizing the natural glucosyl product phlorizin. We focused on aryl-C-glucosides and optimized the analogs, resulting in the discovery of canagliflozin, which is metabolically more stable than T-1095. Canagliflozin markedly induced UGE compared with that of T-1095 because of its excellent pharmacokinetic properties in vivo and its high potency for inhibiting SGLT2. Canagliflozin was selected as a clinical candidate for treating type 2 diabetes mellitus and was approved in the USA and EU in 2013 and in Japan in 2014. In this study, we describe the synthesis of new C-glucoside analogs using a palladium-catalyzed crosscoupling reaction of glucal boronate and its application as an SGLT2 inhibitor.",
author = "Shigeki Sakamaki and Eiji Kawanishi and Sumihiro Nomura",
year = "2016",
month = "1",
day = "1",
doi = "10.5059/yukigoseikyokaishi.74.877",
language = "English",
volume = "74",
pages = "877--884",
journal = "Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry",
issn = "0037-9980",
publisher = "社団法人 有機合成化学協会",
number = "9",

}

TY - JOUR

T1 - Exploration of novel C-glucoside formation and application for SGLT2 inhibitors - Discovery of canagliflozin as a SGL T2 inhibitor

AU - Sakamaki, Shigeki

AU - Kawanishi, Eiji

AU - Nomura, Sumihiro

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Inhibition of sodium glucose co-transporter 2 (SGLT2) in vivo increases urinary glucose excretion (UGE) and controls blood glucose levels in hyperglycemic animals. T-1095 is the first orally active SGLT2 inhibitor, and it was discovered by optimizing the natural glucosyl product phlorizin. We focused on aryl-C-glucosides and optimized the analogs, resulting in the discovery of canagliflozin, which is metabolically more stable than T-1095. Canagliflozin markedly induced UGE compared with that of T-1095 because of its excellent pharmacokinetic properties in vivo and its high potency for inhibiting SGLT2. Canagliflozin was selected as a clinical candidate for treating type 2 diabetes mellitus and was approved in the USA and EU in 2013 and in Japan in 2014. In this study, we describe the synthesis of new C-glucoside analogs using a palladium-catalyzed crosscoupling reaction of glucal boronate and its application as an SGLT2 inhibitor.

AB - Inhibition of sodium glucose co-transporter 2 (SGLT2) in vivo increases urinary glucose excretion (UGE) and controls blood glucose levels in hyperglycemic animals. T-1095 is the first orally active SGLT2 inhibitor, and it was discovered by optimizing the natural glucosyl product phlorizin. We focused on aryl-C-glucosides and optimized the analogs, resulting in the discovery of canagliflozin, which is metabolically more stable than T-1095. Canagliflozin markedly induced UGE compared with that of T-1095 because of its excellent pharmacokinetic properties in vivo and its high potency for inhibiting SGLT2. Canagliflozin was selected as a clinical candidate for treating type 2 diabetes mellitus and was approved in the USA and EU in 2013 and in Japan in 2014. In this study, we describe the synthesis of new C-glucoside analogs using a palladium-catalyzed crosscoupling reaction of glucal boronate and its application as an SGLT2 inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=84992126202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992126202&partnerID=8YFLogxK

U2 - 10.5059/yukigoseikyokaishi.74.877

DO - 10.5059/yukigoseikyokaishi.74.877

M3 - Review article

AN - SCOPUS:84992126202

VL - 74

SP - 877

EP - 884

JO - Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry

JF - Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry

SN - 0037-9980

IS - 9

ER -